Elekta is seeking to acquire Resonant Medical for $28.5 million in cash for the outstanding shares of Resonant, in order to add image guidance technologies, as well as R &D resources in the field of oncology imaging and motion management to its portfolio.
Montreal-based Resonant develops systems for image-guided radiation therapy of soft tissues using 3D ultrasound technology, especially in the breast and pelvic area. According to Stockholm-based Elekta, Resonant’s current products will continue to operate with linear accelerators from other manufacturers.
Resonant was founded in 2000 based on research from McGill University in Montreal. The company’s CEO, Tony Falco, PhD, is one of the founders and has more than 15 years experience in imaging technology. The company has 35 employees, most of whom are based in Montreal.
While the acquisition is subject to customary closing conditions, Elekta expects to consolidate Resonant into its accounts today.